In addition to well-established epithelial endpoints, we are experts in the immunological responses of the airways in vitro and provide reliable and reproducible assessment packages for alveolar macrophages to support a more detailed mechanistic understanding of the safety and fate of inhaled substances in the lung. ImmuPHAGETM is our very own in-house developed immunocompetent cell culture product of the alveoli for enabling next generation inhalation risk assessments.